Keybank National Association OH trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 30.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,450 shares of the company’s stock after selling 3,721 shares during the quarter. Keybank National Association OH’s holdings in Novo Nordisk A/S were worth $362,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of NVO. State Street Corp raised its holdings in shares of Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after buying an additional 5,584,680 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after buying an additional 2,463,300 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after buying an additional 1,331,992 shares during the period. Sustainable Growth Advisers LP raised its holdings in shares of Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock worth $139,482,000 after buying an additional 598,644 shares during the period. Finally, River Road Asset Management LLC raised its holdings in shares of Novo Nordisk A/S by 101.3% in the second quarter. River Road Asset Management LLC now owns 1,120,310 shares of the company’s stock worth $48,050,000 after buying an additional 563,729 shares during the period. Hedge funds and other institutional investors own 6.01% of the company’s stock.

Novo Nordisk A/S (NYSE:NVO) opened at 48.66 on Thursday. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $48.88. The company has a 50-day moving average price of $45.04 and a 200 day moving average price of $40.65. The company has a market cap of $120.69 billion, a PE ratio of 19.66 and a beta of 0.60.

The company also recently announced an annual dividend, which was paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st were given a $0.336 dividend. This is a positive change from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date was Friday, August 18th. This represents a yield of 1.07%. Novo Nordisk A/S’s payout ratio is presently 36.44%.

COPYRIGHT VIOLATION NOTICE: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/14/novo-nordisk-as-nvo-stake-decreased-by-keybank-national-association-oh.html.

Several equities research analysts have recently weighed in on the company. BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, June 15th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Wednesday, June 21st. Finally, Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $56.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.